Abstract
Lethal Toxin Neutralizing Factor (LTNF) isolated from Opossum (Didephis virginiana) has been shown to exhibit anti-venom and anti-allergic property. The small synthetic peptide- LT10 derived from N-terminal of LTNF also showed this property in vivo. We applied molecular modeling, docking and molecular dynamic (MD) simulation techniques to compute the interaction of LT10 peptide with few snake venom enzymes, namely PLA2 from Naja naja and Atrolysin –C from Crotalus atrox. Our in silico interaction analyses provides molecular basis that might account for antivenom activity of LT10 peptide towards these two snake venom toxins. The understanding of such key molecular interactions could be useful for design and development of better anti-snake venom therapies.
Keywords: Atrolysin C, LT10, LTNF, PLA2, snake envenomation, toxin neutralization.
Protein & Peptide Letters
Title:In silico Molecular Interaction Analysis of LTNF Peptide-LT10 with Snake Venom Enzymes
Volume: 21 Issue: 7
Author(s): Sonali G. Chavan and Deepti D. Deobagkar
Affiliation:
Keywords: Atrolysin C, LT10, LTNF, PLA2, snake envenomation, toxin neutralization.
Abstract: Lethal Toxin Neutralizing Factor (LTNF) isolated from Opossum (Didephis virginiana) has been shown to exhibit anti-venom and anti-allergic property. The small synthetic peptide- LT10 derived from N-terminal of LTNF also showed this property in vivo. We applied molecular modeling, docking and molecular dynamic (MD) simulation techniques to compute the interaction of LT10 peptide with few snake venom enzymes, namely PLA2 from Naja naja and Atrolysin –C from Crotalus atrox. Our in silico interaction analyses provides molecular basis that might account for antivenom activity of LT10 peptide towards these two snake venom toxins. The understanding of such key molecular interactions could be useful for design and development of better anti-snake venom therapies.
Export Options
About this article
Cite this article as:
Chavan G. Sonali and Deobagkar D. Deepti, In silico Molecular Interaction Analysis of LTNF Peptide-LT10 with Snake Venom Enzymes, Protein & Peptide Letters 2014; 21 (7) . https://dx.doi.org/10.2174/0929866521666140320112142
DOI https://dx.doi.org/10.2174/0929866521666140320112142 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effect of Vitamin K Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Meta-Analysis
Endocrine, Metabolic & Immune Disorders - Drug Targets Subject Index to Volume 4
Current Genomics Extracellular Matrix Fragments as Regulators of Cartilage Metabolism in Health and Disease
Current Rheumatology Reviews Advances of Paclitaxel Formulations Based on Nanosystem Delivery Technology
Mini-Reviews in Medicinal Chemistry Dilemma of Timing of Administration of Non-Steroidal Anti-inflammatory Agents in Relation to Food in the Prevention of Drug Induced Gastritis: Debusting the Myth
Reviews on Recent Clinical Trials Etiology of Neuroinflammatory Pathologies in Neurodegenerative Diseases: A Treatise
Current Psychopharmacology Heme Oxygenase-1 and Carbon Monoxide: Emerging Therapeutic Targets in Inflammation and Allergy
Recent Patents on Inflammation & Allergy Drug Discovery Limiting Functional Deficiency Following Stroke: Exploiting Different Stem Cell Reservoirs
Current Neuropharmacology MicroRNAs (miRNAs) as Biomarker(s) for Prognosis and Diagnosis of Gastrointestinal (GI) Cancers
Current Pharmaceutical Design Retracted: Effects of Vitamin K2 on Osteoporosis
Current Pharmaceutical Design Chimeric Antigen Receptor-Engineered T-Cells - A New Way and Era for Lymphoma Treatment
Recent Patents on Anti-Cancer Drug Discovery Quilizumab is an Afucosylated Humanized Anti-M1 Prime Therapeutic Antibody
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Personalizing Stem Cell Research and Therapy: The Arduous Road Ahead or Missed Opportunity?
Current Pharmacogenomics and Personalized Medicine On Mechanisms of Reactive Metabolite Formation from Drugs
Mini-Reviews in Medicinal Chemistry Meet Our Editorial Board Member
Current Drug Metabolism Quercetin and Glioma: Which Signaling Pathways are Involved?
Current Molecular Pharmacology Ectopic ATP Synthase in Endothelial Cells: A Novel Cardiovascular Therapeutic Target
Current Pharmaceutical Design Inducible Nitric Oxide Synthase Expression is a Potential Marker for Acute Coronary Syndrome: A Preliminary Study
Current Biomarkers (Discontinued) Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions
Current Drug Targets Advances Towards The Discovery of GPR55 Ligands
Current Medicinal Chemistry